Biodesix annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Biodesix Stock-Based Compensation Growth & History (BDSX)
Biodesix's stock-based compensation was $4.1M for fiscal 2025.
View full Biodesix company overviewBiodesix annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.1M | −$2.5M | −37.65% |
| 2024 | 2024-12-31 | $6.6M | $1.3M | +23.54% |
| 2023 | 2023-12-31 | $5.4M | −$588,000 | −9.86% |
| 2022 | 2022-12-31 | $6.0M | $1.0M | +20.57% |
| 2021 | 2021-12-31 | $4.9M | $1.2M | +33.30% |
| 2020 | 2020-12-31 | $3.7M | $3.5M | +2081.76% |
| 2019 | 2019-12-31 | $170,000 | — | — |
Biodesix quarterly stock-based compensation
Q3.19
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $820,000 | −$219,000 | −21.08% |
| Q1 2026 | 2026-03-31 | $1.1M | $143,000 | +14.71% |
| Q4 2025 | 2025-12-31 | $1.1M | −$190,000 | −15.02% |
| Q3 2025 | 2025-09-30 | $1.1M | −$462,000 | −30.50% |
| Q2 2025 | 2025-06-30 | $1.0M | −$179,000 | −14.70% |
| Q1 2025 | 2025-03-31 | $972,000 | −$1.7M | −63.18% |
| Q4 2024 | 2024-12-31 | $1.3M | $184,000 | +17.02% |
| Q3 2024 | 2024-09-30 | $1.5M | $561,000 | +58.81% |
| Q2 2024 | 2024-06-30 | $1.2M | $161,000 | +15.23% |
| Q1 2024 | 2024-03-31 | $2.6M | $359,000 | +15.74% |
| Q4 2023 | 2023-12-31 | $1.1M | −$996,000 | −47.95% |
| Q3 2023 | 2023-09-30 | $954,000 | −$216,000 | −18.46% |
| Q2 2023 | 2023-06-30 | $1.1M | −$311,000 | −22.73% |
| Q1 2023 | 2023-03-31 | $2.3M | $935,000 | +69.47% |
| Q4 2022 | 2022-12-31 | $2.1M | $810,000 | +63.93% |
| Q3 2022 | 2022-09-30 | $1.2M | −$216,000 | −15.58% |
| Q2 2022 | 2022-06-30 | $1.4M | $829,000 | +153.80% |
| Q1 2022 | 2022-03-31 | $1.3M | −$406,000 | −23.17% |
| Q4 2021 | 2021-12-31 | $1.3M | — | — |
| Q3 2021 | 2021-09-30 | $1.4M | $1.3M | +1286.00% |
| Q2 2021 | 2021-06-30 | $539,000 | $484,000 | +880.00% |
| Q1 2021 | 2021-03-31 | $1.8M | — | — |
| Q3 2020 | 2020-09-30 | $100,000 | $55,000 | +122.22% |
| Q2 2020 | 2020-06-30 | $55,000 | — | — |
| Q3 2019 | 2019-09-30 | $45,000 | — | — |
Biodesix stock-based compensation trends
Over the last five fiscal years, Biodesix's stock-based compensation increased from $3.7M to $4.1M, a change of $430,000. The latest reported quarter, Q2 2026, shows $820,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodesix source filings ↗